Uncategorized

Lysogene communique une mise à jour sur l’étude AAVance qui évalue le LYS-SAF302 chez les patients atteints de MPS IIIA
Lysogene communique une mise à jour sur l’étude AAVance qui évalue le LYS-SAF302 chez les patients atteints de MPS IIIA 150 150 Lysogene

PARIS, France – le 15 octobre 2020 à 08h00 – Lysogene (FR0013233475 – LYS), société…

Lysogene provides update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
Lysogene provides update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA 150 150 Lysogene

PARIS, France – 15 October 2020 at 08:00am – Lysogene (FR0013233475 – LYS), a Phase…

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update
Lysogene Reports First Half 2020 Financial Results and Provides Operational Update 150 150 Lysogene

Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Lysogene annonce ses résultats semestriels 2020 et fait le point sur ses activités
Lysogene annonce ses résultats semestriels 2020 et fait le point sur ses activités 150 150 Lysogene

Trésorerie de 23,8 M€ au 30 juin 2020, renforcée par une augmentation de capital de 7,7 M€ auprès d’OrbiMed et Sarepta, portant la visibilité financière au T4 2021

Lysogene: First Half 2020 Business Update
Lysogene: First Half 2020 Business Update 150 150 Lysogene

Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on…

Lysogene : point d’avancement à la fin du premier semestre 2020
Lysogene : point d’avancement à la fin du premier semestre 2020 150 150 Lysogene

Lysogene société biopharmaceutique de phase 3 s’appuyant sur une plateforme technologique de thérapie génique ciblant les maladies du système nerveux central (SNC)

Bilan Semestriel Du Contrat De Liquidite Contracte Avec La Societe De Bourse Kepler Cheuvreux
Bilan Semestriel Du Contrat De Liquidite Contracte Avec La Societe De Bourse Kepler Cheuvreux 150 150 Lysogene

PARIS, France – 3 juillet 2020 à 18h00 CEST – Lysogene (FR0013233475 – LYS), société…

Lysogene announces a research collaboration with the Weizmann Institute of Science
Lysogene announces a research collaboration with the Weizmann Institute of Science 150 150 Lysogene

Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations…

NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)
NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product This agreement covers the manufacturing of the Adeno-Associated Virus (AAV) 150 150 Lysogene

Lyon and Paris, France, May 26, 2020 – Novasep, a leading supplier of services and…

Lysogene to present its gene therapy technology at the Royal Society of Medicine, London
Lysogene to present its gene therapy technology at the Royal Society of Medicine, London 150 150 Lysogene

April 4th, 2017 14th Medical Innovations Summit FOR IMMEDIATE RELEASE PARIS, France, and CAMBRIDGE, MA,…

  • 1
  • 2

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

Start Typing